CLAIMS

1. Use of an alpha-2 adrenergic agonist in the manufacture of a medicament for improving visual acuity in a mammal in need thereof.

2. Use of an alpha-2 adrenergic agonist in the manufacture of a medicament for improving visual acuity under low-luminance lighting conditions in a mammal in need thereof.

3. Use of an alpha-2 adrenergic agonist in the manufacture of a medicament for improving visual field in a mammal in need thereof.

4. The use according to claim 1, 2, or 3, wherein the alpha-2 adrenergic agonist is a compound that does not have a clinically relevant effect upon pupil size when administered in an amount effective to improve visual acuity or visual field.

5. Use of an alpha-2 adrenergic agonist in the manufacture of a medicament for improving or delaying progressive loss of a measure of visual function under normal lighting or low-luminance lighting conditions without reducing pupil size, in a mammal in need thereof, wherein an improvement or delay of progressive loss of a measure of visual function under normal lighting or low-luminance lighting conditions is experienced by the mammal without a reduction in pupil size.

6. The use according to claim 5, wherein the measure of visual function is contrast sensitivity, or color vision, or performance of vision related tasks.

7. Use of an alpha-2 adrenergic agonist in the manufacture of a medicament for improving visual acuity or visual field without reducing pupil size, in a mammal, wherein an improvement in visual acuity or visual field is experienced by the mammal without a clinically meaningful reduction in pupil size.

8. The use according to claim 7, wherein the mammal has normal vision.

9. The use according to claim 7, wherein the mammal is a human being who has myopia.

10. The use according to any one of claims 1-8, wherein the alpha-2 adrenergic agonist is (S)-(3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl)methanol, or a pharmaceutically acceptable salt or an ester thereof.

11. The use according to claim 9, wherein the alpha-2 adrenergic agonist is [3-[(1*S*)-1-(1H-imidazole-5-yl)ethyl]-2-methylphenyl]methyl-2,2-dimethylpropanoate.

12. The use according to any one of claims 1-11, wherein the mammal is a human being.

13. The use according to claim 12, wherein the human being has glaucoma, or ocular hypertension.

14. The use according to claim 12, wherein the human being has age-related macular degeneration, or a retinal condition associated with decreased low-luminance visual acuity, or geographic atrophy.

15. The use according to any preceding claim, wherein the improvement in visual function, visual acuity, or visual field is experienced within two weeks of receiving the first dose of the alpha-2 adrenergic agonist.